Related by context. All words. (Click for frequent words.) 70 Hsp# inhibitors 66 geldanamycin 65 mTOR inhibitors 64 SERMs 64 antithrombotics 63 direct thrombin inhibitors 63 skeletal metastases 63 proteasome inhibitors 63 vinca alkaloid 63 nucleoside analogues 63 HDAC enzymes 63 isotypes 62 epithelial tumors 62 MEK inhibitors 62 #HT#A 62 ENMD # 62 FLT3 62 myeloproliferative disorders 62 anticancer agents 62 IL 1ß 62 pan HDAC inhibitor 62 JAK inhibitors 62 xenograft models 62 delta isoform 62 erlotinib Tarceva ® 61 nanomolar 61 FGFR2 61 selective inhibitor 61 VEGF receptors 61 tigecycline 61 receptor tyrosine kinase inhibitor 61 nucleoside analogs 61 TNF α 61 myelofibrosis polycythemia vera 61 hepatocellular carcinomas 61 Vidofludimus 61 tumor subtypes 61 TEAEs 61 antiemetics 61 deacetylase inhibitors 61 posaconazole 61 effector function 61 HDAC 61 histologies 61 selective kinase inhibitor 61 HCV genotypes 60 selective inhibitors 60 MMP inhibitors 60 chemotherapeutics 60 factor TNF 60 angiotensin receptor blocker ARB 60 myeloproliferative diseases 60 CCR2 60 calcineurin inhibitors 60 gemcitabine Gemzar 60 receptor antagonists 60 trans retinoic acid 60 adenocarcinomas 60 RNAi therapeutic targeting 60 selective modulator 60 nucleoside analogue 60 mitochondrial toxicity 60 MGd 60 carcinoid tumors 60 humanized monoclonal 60 pneumococcal serotypes 60 interleukins 60 antisense compounds 60 immune modulators 60 PDE4 inhibitors 60 NRTIs 60 selective antagonist 60 induce apoptosis 60 renal tumors 60 PPAR gamma agonists 60 tumor necrosis 60 HuLuc# 60 immunomodulators 60 NNRTIs 60 K ras mutations 60 humanized monoclonal antibody 60 neuroendocrine cancers 60 immunostimulatory 60 basal cell carcinoma BCC 60 HBeAg negative 60 bexarotene 60 IFNs 60 mAbs 60 neoplasms 60 Zolinza 60 interferon IFN 59 paragangliomas 59 receptor subtypes 59 carcinoids 59 intravenous bisphosphonates 59 V#F mutation 59 ErbB 59 TNFa 59 pheochromocytoma 59 metastatic RCC 59 polymerase inhibitors 59 histone deacetylase HDAC inhibitor 59 AT1R 59 histone deacetylase inhibitor 59 missense mutations 59 mycophenolate mofetil 59 SARMs 59 HER2 receptor 59 myelosuppression 59 reverse transcriptase inhibitors 59 bleomycin 59 MORAb 59 tyrosine kinases 59 familial amyloidotic polyneuropathy FAP 59 papillary renal cell carcinoma 59 c MET 59 macrolide antibiotics 59 pro inflammatory cytokines 59 colorectal adenoma 59 hypereosinophilic syndrome 59 sorafenib Nexavar 59 interferons 59 selective antagonists 59 proteins peptides 59 imatinib Gleevec ® 59 Nanobodies 59 insulin sensitizers 59 Preclinical studies suggest 59 serous ovarian cancer 59 cytotoxic 59 VEGF receptor 59 IGFBP 59 microtubule inhibitor 59 invasive fungal infections 59 IL 1β 59 Tyrima 59 AEG# 59 Xanafide 59 cytoprotective 59 pegylated liposomal doxorubicin 59 JAK3 59 myeloproliferative neoplasms 58 Gleevec resistant 58 HER2 overexpression 58 GnRH agonists 58 Azedra 58 humanized antibody 58 endothelin receptor antagonists 58 pharmacokinetic interactions 58 CYT# potent vascular disrupting 58 candidemia 58 DFMO 58 molecularly targeted 58 VEGFR2 58 thalidomide Thalomid 58 anti angiogenic agents 58 oral prodrug 58 invasive candidiasis 58 antimitotic 58 PSN# [002] 58 IGF 1R 58 MTP inhibitor 58 infliximab Remicade 58 nucleoside 58 somatostatin 58 acute coronary syndromes ACS 58 immunomodulating 58 immune modulating 58 HMG CoA reductase inhibitors 58 grade cervical intraepithelial 58 prostate cancer CaP 58 HGPIN 58 VEGF inhibitors 58 chemotherapeutic regimens 58 cytostatic 58 sodium glucose cotransporter 58 NRTI resistance 58 signal transduction inhibitors 58 EGFr 58 lymphoma subtypes 58 protein kinases 58 serotonin receptor 58 HDACi 58 p# inhibitors 58 preclinical xenograft models 58 gastric adenocarcinoma 58 colorectal carcinoma 58 SSc 58 proteasome inhibitor 58 leukemia AML 58 phosphatidylinositol 3 58 NNRTI resistance 58 histologic subtype 58 PI3K inhibitors 58 N. gonorrhoeae 58 peroxisome proliferator activated 58 potently inhibited 58 immunomodulatory 58 androgen receptor AR 58 immunotoxin 58 cisplatin chemotherapy 58 alkylating agent 58 docetaxel Taxotere ® 58 ABCB1 58 chimeric monoclonal antibody 58 selective agonist 58 Symadex 58 M2 subunit 58 histone deacetylase 58 IgG1 antibody 58 microglial activation 58 Interferon alfa 58 anticancer therapies 58 Interferon alpha 58 PARP inhibitors 58 glycosylation profile 58 malignant neoplasms 58 metastatic neuroendocrine tumors 58 invasive ductal 58 kinase inhibition 58 hepatocellular carcinoma HCC 58 echinocandins 58 LNP formulations 58 macrolides 58 immunotoxins 58 ERK signaling 58 antitumoral 58 GISTs 58 JAK inhibitor 58 iNOS 58 KRAS mutations occur 58 renal cell carcinomas 58 Clusterin 58 polymerase inhibitor 58 TNF antagonist 58 Thiovir 58 cardiac toxicity 58 PDGF receptor 58 BCR ABL 58 novel VDA molecule 58 IgG antibodies 58 humanized monoclonal antibodies 58 LTB4 58 chemotherapy induced neutropenia 58 gefitinib Iressa 58 antisense inhibitor 58 quinolones 57 macrovascular events 57 Aurora kinase 57 OMP #M# 57 tumor xenograft models 57 lung carcinomas 57 monoclonal 57 APTIVUS 57 cyclin dependent kinase inhibitor 57 MDR1 57 delafloxacin 57 kidney urologic 57 selective inhibition 57 antithrombotic 57 fluconazole resistant 57 NF kB pathway 57 neutralizing antibody 57 antisense oligonucleotides 57 tyrosine kinase inhibitor 57 TNF inhibitors 57 depsipeptide 57 tyrosine kinase inhibitors 57 peptide antigens 57 GSTP1 57 gastric cancers 57 hepatic metastases 57 HDAC inhibition 57 malignant lymphomas 57 ErbB2 57 synthetic analogues 57 Sym# 57 castrate resistant prostate cancer 57 HCV replicon 57 chlamydial infection 57 MGUS 57 CYP# [002] 57 taxanes 57 oncoproteins 57 IFN alpha 57 HBeAg positive 57 histological subtypes 57 imatinib resistance 57 therapeutic regimens 57 orally bioavailable 57 receptor subtype 57 Nanobody ® 57 TT genotype 57 HCV protease inhibitors 57 non nucleoside 57 cilengitide 57 ADP receptor antagonist 57 kinase inhibitor 57 Glucocorticoids 57 thymalfasin 57 medullary thyroid cancer 57 modulators SERMs 57 antidiabetic 57 HLA DR 57 lipid abnormalities 57 anti mitotic 57 antagomirs 57 CYP #A# 57 radezolid 57 glucose lowering 57 immune modulator 57 hematologic toxicity 57 RNA antagonist 57 chemotherapeutic agents 57 Factor Receptor 57 NS#/#A protease 57 Enterobacteriaceae 57 NS4A 57 systemic lupus erythematosus SLE 57 immunohistochemical staining 57 EpCAM 57 anti CD3 57 CD# antibodies 57 heavily pretreated 57 pertuzumab 57 S/GSK# 57 chronic GVHD 57 cytotoxics 57 immunomodulator 57 diabetic nephropathy 57 ERBB2 57 benzimidazole 57 HCV infection 57 flavopiridol 57 neoplastic 57 receptor inhibitor 57 hematologic disorders 57 potent inhibitors 57 EGFR inhibitors 57 hepatotoxicity 57 Fibroblast Growth Factor Receptor 57 Protease inhibitors 57 HAAH 57 PI3K inhibitor 57 ESBLs 57 HbF 57 anticancer agent 57 azoles 57 Nanobodies ® 57 Myelodysplastic syndromes MDS 57 JAK2 enzyme 57 EGF receptor 57 reuptake inhibitors 57 HIV integrase inhibitors 57 investigational monoclonal antibody 57 targeting CD# 57 osteosarcomas 57 systemically administered 57 Hsp# inhibitor 57 severe hypersensitivity reactions 57 TLR9 agonist 57 kinase inhibitors 57 beta lactam 57 HCV infections 57 cyclin E 56 ADPKD 56 Pertuzumab 56 pancreatic adenocarcinoma 56 hypercalcemia 56 EphA2 56 VZV 56 CEQ# 56 HER2 expression 56 TRAIL R2 56 erlotinib Tarceva 56 histone deacetylase HDAC 56 apoptotic pathway 56 Pneumocystis carinii pneumonia 56 protein kinase inhibitor 56 antiangiogenic 56 metaglidasen 56 polycythemia vera PV 56 A3 adenosine receptor 56 capsular polysaccharide 56 CD# antibody [001] 56 mRNA expression 56 PBMCs 56 Enzastaurin 56 advanced adenomas 56 IL# PE 56 HDACs 56 biologic pathway 56 rotaviruses 56 Carfilzomib 56 calcitriol 56 Dapagliflozin 56 TTR amyloidosis 56 beta interferons 56 nonmelanoma skin cancers 56 BMS # 56 endometrial hyperplasia 56 lymphoid malignancies 56 herpes zoster shingles 56 vWF 56 antitumor 56 hyperoxaluria 56 estrogen receptor beta 56 telomerase inhibitor 56 Abeta# 56 systemic fungal infections 56 EGFR mutations 56 retaspimycin hydrochloride 56 humanized anti 56 enzyme inhibitors 56 Epothilones 56 small molecule activators 56 malignancies 56 multi kinase inhibitor 56 LY# [002] 56 preclinically 56 pulmonary metastases 56 Abeta peptide 56 epithelial ovarian cancer 56 cytotoxin 56 IgG4 56 MAb 56 eotaxin 56 busulfan 56 investigational humanized monoclonal antibody 56 chemotherapeutic drug 56 angiotensin converting enzyme inhibitors 56 glioblastoma multiforme GBM 56 receptor PPAR 56 mRCC 56 NSCLC tumors 56 heparanase 56 isoforms 56 CYC# 56 elastase 56 chemically modified siRNA 56 sporadic ALS 56 oral JAK1 56 cytotoxicity 56 monoclonal anti 56 allogeneic HSCT 56 enzyme inhibitor 56 Gefitinib 56 muscarinic 56 HER2/neu 56 S#P# 56 HSP# inhibitors 56 antidiabetic drugs 56 thiazolidinediones 56 Candida infection 56 CCR5 antagonist 56 Th2 cytokines 56 PARP inhibition 56 cyclooxygenase 56 signaling cascades 56 cranial irradiation 56 angiogenesis inhibitor 56 hematologic malignancies 56 idiopathic myelofibrosis 56 atrophic gastritis 56 cytokine IL 56 renin inhibitors 56 breast cancer subtypes 56 IgG1 56 immune stimulatory 56 immunomodulatory effects 56 Blinatumomab 56 histone deacetylase HDAC inhibitors 56 intradermal injection 56 recurrent glioblastoma multiforme 56 cytokines IL 56 HMG CoA reductase 56 JAK#/JAK# 56 endothelin receptor 56 breast carcinomas 56 Pseudomonas aeruginosa infections 56 cytotoxic agents 56 serogroups 56 lymphocytosis 56 essential thrombocythemia 56 CD# monoclonal antibody 56 humanised monoclonal antibody 56 enkephalin 56 hepatoma 56 potent inhibitor 56 MTHFR 56 Hedgehog pathway 56 selective estrogen receptor 56 L asparaginase 56 heparins 56 splice variants 56 Chemokine Receptor 56 CCX# 56 retaspimycin 56 antisense inhibitors 56 receptor agonists 56 phosphate S1P 56 nanoviricide drug 56 Fc fusion protein 56 antibody 56 vascular disrupting agents 56 NXL# 56 thromboembolic events 56 Tumor Necrosis Factor 56 Epidermal Growth Factor Receptor 56 cisplatin resistant 56 colorectal liver metastases 56 Anticalins R 56 neoplasm 56 genetic polymorphisms 56 ALN TTR 56 IAP inhibitors 56 radiolabeled monoclonal antibody 56 microRNA miR 56 kinases 56 cell lymphomas 56 lymphoid tumors 56 Nanobody 56 CD3 monoclonal antibody 56 lupus nephritis 56 Debio 56 hamartomas 56 IGF IR 56 Upregulation 56 lymphomas 55 proteases 55 Multimeric 55 subtypes 55 pertussis toxin 55 pediatric acute lymphoblastic 55 P#X# 55 dysglycemia 55 PTHrP 55 insulin analogues 55 miRNA molecules 55 carcinoid 55 anti CD# antibodies 55 transgenic rats 55 ADAMTS# 55 HCV polymerase inhibitors 55 lymphoid cells 55 protease inhibitors 55 prognostic markers 55 colorectal carcinomas 55 potent inhibition 55 steatohepatitis 55 gastric carcinogenesis 55 atherothrombosis 55 promoter methylation 55 HLA B# 55 JAK2 inhibitor 55 ovarian breast 55 Prostaglandins 55 PPARgamma 55 homozygotes 55 oral antiviral 55 HDAC inhibitors 55 alpha interferon 55 astrocytomas 55 MAPK pathway 55 mediated inhibition 55 small molecule inhibitors 55 preclinical models 55 interferon lambda 55 atherosclerotic lesions 55 nanoviricides 55 trivalent influenza vaccine 55 Aviptadil 55 interleukin IL -# 55 nucleosides 55 GPCR targets 55 novel peptide 55 biochemical abnormalities 55 N methyl 55 gamma secretase inhibitors 55 IMA# 55 siRNAs targeting 55 lapatinib Tykerb 55 NKG2D 55 Anticalins 55 chemotherapeutic agent 55 monogenic 55 exocrine pancreas 55 Curaxins 55 mertansine 55 CDK inhibitor 55 CBLC# 55 transgene expression 55 DNA intercalator 55 receptor antagonist 55 seminomas 55 protein interleukin 55 kallikrein 55 isoenzymes 55 histone deacetylase inhibitors 55 DermaVir Patch 55 seminoma 55 cytopathic 55 lymphoproliferative disorders 55 huC# DM4 55 distant metastasis 55 neurological manifestations 55 neuroblastomas 55 nucleotide analogs 55 activin 55 haematological malignancies 55 cytotoxic chemotherapy 55 YONDELIS R 55 prescribed proton pump 55 cardiotoxicity 55 Medullary thyroid cancer 55 superficial bladder cancer 55 reversible inhibitor 55 murine models 55 Fas ligand 55 investigational therapies 55 HDAC6 55 clade B 55 potent cytotoxic 55 relapsed ovarian cancer 55 siRNA compounds 55 glycolipids 55 Factor VIIa 55 BCR ABL mutations 55 bronchogenic carcinoma 55 K#R [002] 55 FGFR 55 beta agonists 55 retinoic acid receptor 55 CagA 55 protein tyrosine phosphatase 1B 55 proliferative disorders 55 ependymomas 55 cardioprotective effects 55 metastatic gastric 55 gene polymorphism 55 thrombophilia 55 imatinib Gleevec 55 CMV infection 55 5alpha reductase 55 enveloped viruses 55 malignant pleural mesothelioma 55 JAK2 55 leiomyomas 55 ovarian carcinoma 55 TNFalpha 55 histological subtype 55 PIK3CA 55 PDGFR 55 adenoviral 55 selective androgen receptor modulators 55 muscarinic receptors 55 receptor blockers 55 MUC1 55 serine threonine 55 c KIT 55 BAY #-# 55 bevacizumab Avastin ® 55 standard chemotherapy regimens 55 NEUGENE 55 histologic subtypes 55 inhibiting tumor 55 HER2 positive metastatic breast 55 glitazones 55 chronic periodontitis 55 M2e 55 phospholipid 55 chronic eosinophilic leukemia 55 SCCHN 55 selectively inhibits 55 oncolytic 55 rituximab Rituxan 55 CLL cells 55 tubulin inhibitor 55 cyclin dependent kinases 55 monoclonal antibody mAb 55 T1DM 55 CD#b 55 neuraminidase inhibitor 55 functional polymorphism 55 H#K#me# 55 antiviral efficacy 55 virus AAV 55 Aurora kinase inhibitor 55 EGFR mutation 55 herpesviruses 55 JAK1 55 molecular subtypes 55 antiplatelet drugs 55 COX2 55 pCR 55 brostallicin 55 multitargeted 55 pDCs 55 Epstein Barr virus EBV 55 c MYC 54 RRM1 54 HQK 54 CDK4 54 cholangiocarcinoma 54 PKCi 54 hemorrhagic fever viruses 54 clinicopathological 54 synthetic retinoid 54 HepG2 cells 54 interferon γ 54 tumoral 54 isotype 54 antisense drug 54 molecular abnormalities 54 HNSCC 54 rs# [004] 54 prostanoid 54 PI3K/mTOR 54 FasL 54 coinfection 54 CCR9 antagonist 54 anticancer compounds 54 NTDDS 54 locoregional recurrence 54 BiTE 54 tumorigenic 54 vasodilators 54 HepDirect prodrug 54 metastatic renal cell carcinoma 54 JAK2 inhibitors 54 KRAS mutations 54 prognostic marker 54 receptor agonist 54 etiologies 54 IMPDH 54 S. aureus isolates 54 cell lymphoma ALCL 54 PARP inhibitor 54 oncogenic HPV types 54 macrocycles 54 HPV# 54 C5aR 54 colorectal adenomas 54 protease inhibitor 54 bioactive lipids 54 beta lactamases 54 chemopreventive agents 54 sulphonylureas 54 familial clustering 54 neuroendocrine tumors 54 HSP# inhibitor 54 transient receptor 54 epothilone 54 E selectin 54 NFκB 54 B7 H3 54 antibody titers 54 p# inhibitor 54 hemorrhagic complications 54 glucagon receptor 54 TLR9 agonists 54 PTPN# 54 TGF beta signaling 54 pathogenic mechanisms 54 antiproliferative activity 54 transplantation HCT 54 serine threonine kinases 54 GAP #B# 54 lung adenocarcinomas 54 BRAF mutation 54 immunological diseases 54 Akt activation 54 TTR gene 54 Squamous 54 selective orally bioavailable 54 insulin sensitizing 54 recurrent ovarian cancer 54 Onconase 54 tumor antigen 54 anti EGFR antibody 54 GvHD 54 HLA DRB1 * 54 BAL# [001] 54 heavily pretreated patients 54 clinically validated targets 54 immunopathology 54 leukotriene 54 miR #a [002] 54 mycosis fungoides 54 TKM ApoB 54 CB1 antagonists 54 inverse agonist 54 activating mutations 54 renin inhibitor 54 activated lymphocytes 54 fluoroquinolone resistance 54 TLR8 54 CTGF 54 peripheral blood mononuclear 54 metalloprotease 54 ALN TTR# 54 nonalcoholic steatohepatitis NASH 54 replicon 54 radionuclide therapy 54 thrombopoietin 54 thyroid hormone receptor 54 autoantibody 54 IgA deficiency 54 tumor histology 54 Trichomonas vaginalis 54 small molecule inhibitor 54 Protein Kinase C 54 serine proteases 54 tyrosine kinase receptor 54 ALK mutations 54 HDAC inhibitor 54 receptor modulators 54 IL 1beta 54 bronchial epithelial cells 54 C. trachomatis 54 immunomodulatory properties 54 coinfected 54 PCa 54 HCV protease inhibitor 54 xenograft tumors 54 locoregional 54 metastatic colorectal 54 factor Xa 54 fulvestrant 54 oxysterols 54 nanomolar range 54 Anticalins ® 54 outer membrane proteins 54 mutated K ras 54 5HT 54 RhuDex ® 54 topoisomerase 54 Toxicities 54 E#F# 54 squamous 54 bortezomib 54 act synergistically 54 mTOR mammalian target 54 myeloma cells 54 receptor blocker 54 GBM tumors 54 endostatin 54 HER2 positive cancers 54 serotype #A 54 cellular cytotoxicity 54 Polymorphisms 54 bevacizumab Avastin 54 tumor specific antigen 54 IGFBP 3 54 antisense oligonucleotide 54 bone metastasis 54 imetelstat 54 RAF kinase 54 Carcinoid tumors 54 itraconazole 54 gastrointestinal stromal tumors GISTs 54 syngeneic 54 neoplastic lesions 54 ALK inhibitor 54 prostate carcinoma 54 Gliomas 54 interferon alpha 54 hypoxia inducible factor 54 LHRH receptor positive 54 daptomycin 54 ANCA associated 54 thrombin receptor 54 autoantibodies 54 serogroup 54 tumors GIST 54 sarcomatoid 54 CMV disease 54 tricyclic 54 SGLT2 54 malignant neoplasm 54 LEX System 54 HCV protease 54 diagnostic biomarker 54 Elvitegravir 54 EBV infection 54 unresectable tumors 54 pro angiogenic 54 immunosuppressive 54 dAbs 54 hepatocellular carcinoma 54 mutated KRAS gene 54 metastatic melanomas 54 PTEN mutations 54 multidrug resistance 54 monocytic 54 Aß 54 hormonal therapies 54 mucinous 54 chlamydial 54 imatinib resistant 54 PI3K Akt 54 taxol 54 axitinib 54 targeted radiotherapeutic 54 phosphatases 54 CD8 responses 54 RNA antagonists 54 protein tyrosine phosphatase 54 medulloblastomas 54 muscular dystrophies 54 IL6 54 thyroid carcinoma 54 novel anticancer 54 beta adrenergic 54 selective NSAIDs 54 costimulation 54 carcinomas 54 monoclonal antibodies 54 histone deacetylases 54 Leukemias 54 acute leukemias 54 pharmacologic 54 GPNMB 54 TRAIL R1 54 5 HT2A 54 ovarian lung 54 PEG SN# 54 adenomatous 54 channel blockers 54 coagulation disorders 54 oncoprotein 54 lung adenocarcinoma 54 oxidative stress inducer 54 methicillin susceptible Staphylococcus aureus 54 metastatic lymph nodes 54 dasatinib Sprycel 54 gene polymorphisms 54 sphingolipid 54 cytochrome P# 54 tumor necrosis factor 54 clusterin 54 haematopoietic 54 Raltegravir 54 selective agonists 54 BRAF inhibitor 54 HER3 54 acute GvHD 54 anticonvulsants 54 hematological diseases 54 urothelial cancer 54 Genotypes 54 valproic acid 53 Smac mimetics 53 node metastases 53 HIV integrase inhibitor 53 prostate cancer PCa 53 arterial calcification 53 potently inhibit 53 antibody fragment 53 invasive carcinomas 53 c myc 53 BCR ABL inhibitors 53 selectively inhibit 53 serine protease 53 inhibitory effects 53 CD4 + CD# 53 anemias 53 potent anticancer 53 dinucleotide 53 integrase inhibitor 53 alkylating agents 53 ESBA# 53 androgen deprivation 53 breast carcinoma 53 IAP inhibitor 53 PTP 1B 53 GRN#L 53 BRAF mutations 53 isoform 53 cervical carcinoma 53 IFN gamma 53 Leydig cell 53 liposomal 53 PSMA ADC 53 Lenalidomide 53 cyclin dependent kinase 53 nonsmall cell lung cancer 53 UsiRNAs 53 serum antibodies 53 TLR agonists 53 chemotherapeutic drugs 53 sigma receptors 53 ligand TRAIL 53 cystatin 53 Renal Cell Carcinoma RCC 53 poor metabolizers 53 breast pancreatic 53 anti fibrotic 53 histone methyltransferases HMTs